Humacyte director granted 80,000 options at $1.08

Humacyte, Inc. director Kathleen Sebelius reported a grant of stock options representing the right to buy 80,000 shares of common stock.

Accepted by SEC EDGAR 06/12/2026 - 05:56 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Humacyte, Inc. director Kathleen Sebelius reported a grant of stock options representing the right to buy 80,000 shares of common stock. The options have an exercise price of $1.08 per share and expire on June 11, 2036.

According to the vesting terms, the first 25% of the option becomes exercisable on June 11, 2027, and the remaining portion vests in equal monthly installments on the 11th of each month through June 11, 2030. Following this grant, Sebelius holds 80,000 stock options directly.

Insider Trade Summary

Grant/Award: 80,000 shares

Grant/Award 1 txn

Insider Sebelius Kathleen

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (right to buy)	80,000	$0.00	$0.00

Holdings After Transaction: Stock Options (right to buy) — 80,000 contracts (Direct)

Holdings Before and After: Stock Options (right to buy), 0 to 80,000 contracts (Direct)

Footnotes (1)

1. F1. The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Humacyte (HUMA) director Kathleen Sebelius report in this Form 4 filing?

Kathleen Sebelius reported receiving a grant of stock options for 80,000 shares of Humacyte common stock. These options are a compensation award, not an open-market share purchase or sale, and give her the right to buy shares at a fixed exercise price.

How many Humacyte (HUMA) stock options were granted to Kathleen Sebelius and at what price?

She was granted stock options covering 80,000 shares of Humacyte common stock. The options carry an exercise price of $1.08 per share, meaning she can buy shares at that price once the options vest and before they expire.

What is the vesting schedule for Kathleen Sebelius’s Humacyte (HUMA) stock options?

The options vest over several years. The first 25% becomes exercisable on June 11, 2027, and the remaining portion vests in equal monthly installments on the 11th of each month through June 11, 2030, creating a gradual vesting timeline.

When do Kathleen Sebelius’s Humacyte (HUMA) stock options expire?

These stock options expire on June 11, 2036 if not exercised earlier. After that expiration date, she would no longer have the right to purchase Humacyte common stock at the set $1.08 per share exercise price from this grant.

Does the Form 4 show Kathleen Sebelius buying or selling Humacyte (HUMA) shares on the market?

The filing shows a grant of stock options as compensation, classified as an acquisition of derivative securities. It does not report any open-market purchases or sales of Humacyte common stock, only the award of options that may be exercised in the future.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sebelius Kathleen

(Last) (First) (Middle)

2525 EAST NORTH CAROLINA HIGHWAY 54

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Humacyte, Inc. [ HUMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$1.08	06/11/2026		A		80,000		(1)	06/11/2036	Common Stock	80,000	$0	80,000	D

Explanation of Responses:

1. The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030.

	/s/ Kathleen Sebelius by Dale A. Sander as Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)